Eureka Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Eureka Therapeutics, Inc. - overview
Established
2006
Location
Emeryville, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2006, Eureka Therapeutics, Inc. is a clinical-stage biotechnology company. Dr. Cheng Liu is the founder and current President and CEO of the company.
In December 2019, Eureka Therapeutics, Inc. raised USD 45 million in Series E funding led by new investor Lyell Immunopharma, Inc. , with participation from other unspecified investors. The company focuses on creating new T cell treatments for cancer treatment.
Its main technology focuses on the discovery and development of potentially safer and more effective T cell treatments for the treatment of solid tumors and hematologic malignancies using its patented ARTEMIS AbTCR T cell receptor platform and E-ALPHA antibody discovery platform. Following the Series E funding closed in March 2020, the company will use the proceeds to advance its proprietary TCR-mimic and antibody-TCR ARTEMIS programs, including Eureka’s anti-AFP ARTEMIS Phase I/II clinical trial in the United States for the treatment of hepatocellular carcinoma (HCC).
Current Investors
GP Capital, Acorn Pacific Ventures, Lyell Immunopharma, Inc.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Epidemiology, Oncology/Cancer Treatment
Website
www.eurekainc.com
Verticals
HealthTech
Company Stage
Series E
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.